BITS Pilani

  • Page last updated on Friday, October 29, 2021

Reviews

banner
Review Articles

List of Review Articles

  • Chlorosulfonyl isocyanate: A novel reagent for the synthesis of heterocycles 2, Kamal, A.; Sattur, P. B., Heterocycles 1987, 26, 1051 
  • Recent advances in the synthetic uses of chlorocarbonyl isocyanate, Kamal, A., Heterocycles 1990, 31, 1377
  • The newer synthetic strategies for DNA binding pyrrolobenzodiazepine antibiotics, Kamal, A.; Rao, M. V.; Reddy, B.S.N., Chemistry of Heterocyclic Compounds1998, 12, 1588
  • Recent developments in the design, synthesis and structure activity relationship studies of pyrrolo[2,1-c][1,4]benzodiazepines as DNA-interactive antitumor antibiotics, Kamal, A.; Rao, M. V.; Laxman, N.; Ramesh, G.; Reddy, G.S.K., Current Medicinal Chemistry 2002, 2, 215
  • Recent advances in the solid-phase combinatorial synthetic strategies for the quinoxaline, quninazoline and benzimidazole based privileged structures, Kamal, A.; Reddy, K. L.; Devaiah, V.; Shankaraiah, N.; Rao, M. V., Mini-Reviews in Medicinal Chemistry 2006, 6, 71 
  • Recent Advances in the solid-phase combinatorial synthetic strategies for the benzodiazepine based privileged structures, Kamal, A.; Reddy, K. L.; Devaiah, V.; Shankaraiah, N.; Reddy, D.R.S., Mini-Reviews in Medicinal Chemistry2006, 6, 53 
  • Approaches based on enzyme mediated kinetic to dynamic kinetic resolutions: A versatile route for chiral intermediates, Kamal, A.; Azhar, M. A.; Krishnaji, T.; Malik, M. S.; Azeeza, S., Coord.Chem.Rev.2008,252, 569
  • Efforts towards the development of new antitubercular agents: Potential for thiolactomycin based compounds, Kamal, A.; Azeeza, S.; Malik, M. S.; Shaik, A. A.; Rao, M. V., J. Pharm. Pharmaceut. Sci. 2008, 11, 106 
  • New therapeutics: Potential for drug resistant tuberculosis, Kamal, A.; Azeeza, S.; Malik, M. S.; Faazil, S., International Journal of Medical and Biological Frontiers 2010, 535
  • Search for new & novel chemotherapeutics for the treatment of human malignancies, Kamal, A.; Azeeza, S.; Bharathi, E. V.; Malik, M. S.; Shetti, R.V.C.R.N.C., Mini-Reviews in Medicinal Chemistry 2010, 405
  • p53-Mdm2 inhibitors: Patent review (2009-2010), Kamal, A.; Azhar, M. A.; Shaik, T. B., Expert Opinion on Therapeutic Patents, 2012, 22, 95
  • Recent advances on structural modifications of benzothiazoles and their conjugate systems as potential chemotherapeutics, Kamal, A.; Srikanth, Y.V.V.; Khan, M.N.A.; Sultana, F.; Reddy, M. K., Expert Opin. Investig. Drugs, 2012, 21, 619
  • Naphthalimide derivatives with therapeutic characteristics: a patent review, Kamal, A.; Narasimha, B. R.; Srikanth, P. S.; Srivastava, A. K., Expert Opinion on Therapeutic Patents, 2013, 23, 299
  • The design and development of imidazothiazole-chalcone derivatives as potential anticancer drugs, Kamal, A.; Reddy, M. K.; Viswanath, A., Expert Opinion on Investigational Drugs, 2013, 8, 289 
  • Apoptosis-inducing agents: a patent review, Kamal A.; Faazil S.; Malik, M. S.; Expert Opinion on Therapeutic Patents. 2013, 24, 339
  • Tankyrase inhibitors as therapeutic targets for cancer. Kamal A.; Riyaz Sd.; Srivastava A.K.; Rahim A.; Current Topics in Medicinal Chemistry. 2014,14, 1967 
  • Recent developments towards podophyllotoxin congeners as potential apoptosis inducers, Kamal, A; Hussaini, S.M.A; Malik, M.S; Anti-Cancer Agents Med. Chem. 2015, 15, 565 
  • Therapeutic potential of benzothiazoles:  a patent review (2010-2014), Kamal, A; Hussaini, S.M.A; Malik, M.S; Expert Opinion on Therapeutic Patents. 2015, 25, 335 
  • Podophyllotoxin derivatives: a patent review (2012-2014), Kamal, A; Hussaini, S.M.A; Rahim, A; Riyaz, Sd., Expert Opinion on Therapeutic Patents, 2015, 25, 1025
  • Embracing synthetic lethality for novel anticancer therapies, Kamal, A; Shaik, T.B; Malik, M.S; Expert Opinion on Drug Discovery, 2015, 10, 1119
  • Recent advances in combretastatins based derivatives and prodrugs as antimitotic agents, Seddigi, Z.S; Malik, M.S; Prashanth, S.A; Ahmed, S; Babalghith, A.O; Lamfon, H.A; Kamal, A., Med. Chem. Commun., 2017, 8, 1592
  • Lipases in asymmetric transformations: Recent advances in classical kinetic resolution and lipase-metal combinations for dynamic processes. Seddigi, Z.S.; Malik, M.S.; Ahmed, S.A.; Babalghith, A.O.; Kamal, A., Coord.Chem.Rev., 2017, 348, 54.
  • Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions, Prashanth, S.A; Harikrishna, N;  Hussaini, S.M.A; Babu, B.N; Kamal, A., Eur. J. Med. Chem. 2018, 144, 843-858.
  • Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Sultana, F; Manasa, K. L.; Shaik, S.P.; Bonam S. R; Kamal, A., Curr. Med. Chem., 2019, 26, 7212.
  • Peptides as potential anticancer agents. Aaghaz, S;Gohel, V; Kamal, A., Curr. Top. Med. Chem., 2019 (in press).
  • Combretastatin based compounds with therapeutic characteristics: a patent review.  Nainwal, L.M., Alam, M. M., Shaquiquzzaman, M; Marella, A; Kamal, A., Expert Opinion on Therapeutic Patents, 2019, 29, 703.
  • Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018). Haider, K; Rahaman, S; Yar, M.S.; Kamal, A; Expert Opinion on Therapeutic Patents, 2019, 29, 623.
  • Application of triazoles as bioisoteres and linkers in the development of microtubule targeting agents. Malik, M. S.; Ahmed, S.A.; Seddigi, Z. S.; Ansari, M. A.; Kamal, A., RSC Med.Chem. 2020, 11, 327.
  • A Comprehensive Review on the Therapeutic Versatility of Imidazo[2,1-b]-thiazoles. Shareef, M.A.; Khan, I.; Babu, B.N.; Kamal, A., Current Medicinal Chemistry, 2020 (in press).
  • Synthetic Lethality on Drug Discovery: an update on Cancer Therapy. Yar, M.S.; Haider, K.; Gohel, V.; Siddiqui, N.A.; Kamal, A., Expert Opinion on Drug Discovery, 2020, 15, 823.
  • β-Carbolines as potential anticancer agents, Aaghaz, S.; Sharma, K.; Jain, R.; Kamal, A., Eur. J. Med. Chem., 2021, 216, 113321. 
  • Novel approaches to the development of direct KRAS inhibitors: Structural insight and drug design. Sharma, A.; Yakkala, P.A.; Yar, M.S.; Shafi, S.; Kamal, A., Expert Opinion on Drug Discovery, 2021, (in press).

Quick Links

    An Institution Deemed to be University estd. vide Sec.3 of the UGC Act,1956 under notification # F.12-23/63.U-2 of Jun 18,1964

    © 2022 Centre for Software Development,SDET Unit, BITS-Pilani, India.

    Designed and developed by fractal | ink design studios